School of Pharmacy
Dr. Xue earned his BS in chemistry from the University of Science and Technology of China in 2001. He completed his PhD in chemistry at Brown University in 2007, and later pursued a post-doctoral fellowship in medicinal chemistry at Northwestern University from 2007 to 2009.
Dr. Xue is currently using experimental methods from organic chemistry and medicinal chemistry to develop small molecule therapeutic agents for various diseases including traumatic brain injury (TBI) and other neurological disorders.
Lab Techniques and Equipment:
Organic synthetic lab
Grants & Contracts:
07/01/2013 - 06/30/2015
University of Maryland Pilot and Exploratory Interdisciplinary Research (IDR) Award
Project Title: "Positive Allosteric Modulators (PAMs) of Metabotropic Glutamate Receptor 5 (mGluR5) for Traumatic Brain Injury (TBI)"
This research centers upon the development of small molecule PAMs of mGluR5 as delayed treatment of TBI
- Sun, X.; Rai, R.; MacKerell, Jr., A. D.; Faden, A. I.; Xue, F. "Facile One-Step Synthesis of 2,5-Diketopiperazines" Tetrahedron Lett. 2014, 55, 1905-1908.
- He, X.; Xue, F. "Transition-Metal-Free Synthesis of (Z)-3-Ylidenephthalides from 2-Acyl-Benzoic Acids" Tetrahedron Lett. 2014, 55, 1956-1958.
- Sun, X.; Rai, R.; Deschamps, J. R.; MacKerell, Jr., A. D.; Faden, A. I.; Xue, F. "Boc-Protected 1-(3-Oxocycloalkyl)ureas via a One-Step Curtius Rearrangement: Mechanism and Scope" Tetrahedron Lett. 2014, 55, 842-844.
- Lakkaraju, S. K.; Xue, F.; MacKerell, Jr., A. D. "Estimation of Ligand Efficacies of Metabotropic Glutamate Receptors from Conformational Forces Obtained from Molecular Dynamics Simulations" J. Chem. Info. Model. 2013, 53, 1337-1349.
- Hom, K.; Heinzl, G. A.; Suntara, E.; Pedro, L.; Xue, F.; MacKerell, Jr., A. D.; Wilks, A. "Small Molecule Antivirulents Targeting the Iron-Regulated Heme Oxygenase (HemO) of P. Aeruginsa" J. Med. Chem. 2013, 54, 1700-1703.
- Xue, F.; Stoica, B. A.; Hanscom, M.; Kabadi, S. V.; Faden, A. I. "Positive Allosteric Modulators (PAMs) of Metabotropic Glutamate Receptor 5 (mGluR5) Attenuate Microglial Activation" CNS & Neurol. Disord. Drug Targets 2014, in press.